In Vitro Activities of Moxifloxacin and Other Fluoroquinolones against Mycoplasma pneumoniae

AUTOR(ES)

Hamamoto, Kumiko

FONTE

American Society for Microbiology

RESUMO

A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC50 and MBC50) and 0.3 μg/ml (MIC90 and MBC90) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.

Documentos Relacionados

• In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
• In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.
• In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae
• In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
• In Vitro Activities of Quinupristin-Dalfopristin and the Streptogramin RPR 106972 against Mycoplasma pneumoniae